Argenx's Vyvgart Trial Setback is Major Negative Surprise
Dow Jones
3 hours ago
1125 GMT - Argenx's decision to stop a late-stage clinical trial of its Vyvgart drug in Sjogren's disease comes as a major negative surprise for the European biotech company, UBS analysts say in a note. "We believe Argenx's discontinuation of Sjogren's study at interim suggests potentially very little efficacy--if any--not just a 'near miss'," the analysts say. The drug had generated positive and solid results in a midstage study, as had a similar medicine from rival Johnson & Johnson, Imaavy, they add. The study was supposed to be one of the most closely watched updates from Argenx next year, and UBS had modeled peak annual sales for Vyvgart in Sjogren's at $3.5 billion, the analysts say. Shares fall 16%.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.